ELEdelgard Lindhoff-Last

Edelgard Lindhoff-Last

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Edelgard Lindhoff-Last has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Peak and baseline concentrations of fondaparinux during prophylactic therapy

    by R. Kanagendran, J. Scheuermann, H. Ackermann, R. Kaufmann, W.-H. Boehncke, R. J. Ludwig, M. Schindewolf, Z. Wolf, E. Lindhoff-Last

    Fondaparinux is widely approved for prophylaxis and treatment of venous thromboembolic events (VTE). However, its longer half-life time compared to heparins limits its peri-procedural use. Aim: To investigate 3h peak and 24h baseline concentrations of fondaparinux when administered for prophylaxis (1 x 2.5 mg qd). Secondary outcome measures: incidences of VTE, bleedings, HIT, allergic skin reactions, 30 days mortality. Patients, methods: Between 02/2010 and 03/2011, 3h peak and 24h baseline levels of fondaparinux were measured with a chromogenic anti-FXa method in 75 consecutive patients. Medical data were obtained from patients' records. Results: The 5% and 95% percentile of the 3h peak level were 0.20 μg/ml and 0.83 μg/ml (median: 0.53 μg/ml), and of the 24h baseline level 0.08 μg/ml and 0.53 μg/ml (median 0.21 μg/ml), respectively. An inverse correlation was found between fondaparinux levels and GFRs (rho=-0.617 (3h); rho=-0.648 (24h); p=0.01). Shorter (≤5 days) or longer (≥8 days) duration of prior fondaparinux exposure showed no significantly different 3h peak/24h baseline levels (p>0.6). One progressive thrombosis occurred but no major bleedings, HIT, allergic skin reactions or fatalities. Conclusions: After fondaparinux exposure, >75% of the patients still had relevant prophylactic 24h baseline levels. This did not coincide with a high rate of bleeding events. Due to the low patient number in this study undergoing surgery or interventions, it remains to be investigated whether or at which concentrations the bleeding risk is increased when baseline levels are within prophylactic ranges. Hintergrund: Das synthetische Pentasaccharid Fondaparinux, ein indirekter Faktor Xa-Inhibitor, besitzt eine breite Zulassung in der Prophylaxe und Therapie von thromboembolischen Komplikationen. Es hat ein deutlich niedrigeres Risiko für HIT und allergische Reaktionen im Vergleich zu Heparinen. Allerdings bestehen aufgrund seiner längeren Halbwertszeit Einschränkungen im peri-operativen und -inter-ventionellen Bereich, während es für Heparine klare Bridging-Empfehlungen gibt. Ziel der Untersuchung war es, die 3h-Gipfelund 24h-Talspiegel unter prophylaktischer Fondaparinuxgabe (1 x 2,5 mg/die) und die Häufigkeiten hierunter auftretender Komplikationen (venöse thromboembolische Komplikationen, Blutungen, HIT, allergische Hautreaktionen, 30-Tages-Mortalität) zu ermitteln. Patienten, Methoden: Zwischen Februar 2010 und März 2011 wurden bei 75 konsekutiven internistischen und chirurgischen Patienten Fondaparinux 3h-Gipfel- und 24h-Talspiegel mittels einer chromogenen anti-FXa-Methode gemessen. Die Erhebung der medizinischen Daten sowie der Komplikationen erfolgte aus den Krankenakten. Ergebnisse: Die 5% und 95% Perzentilen der 3h Gipfelspiegel lagen bei 0,20 μg/ml bzw. 0,83 μg/ml (Median: 0,53 μg/ml), und der 24h Talspiegel bei 0,08 μg/ml bzw. 0,53 μg/ml (Median: 0,21 μg/ml). Sie waren signifikant, invers negativ mit der glomerulären Filtrationsrate (GFR) korreliert (Spearman Korrelationskoeffizient: rho=-0.617 (3h); rho=-0.648 (24h), p= 0.01) Es ergaben sich keine signifikanten Unterschiede hinsichtlich der gemessenen Fondaparinuxkonzentrationen bei kürzerer (≤ 5 Tage) oder längerer (≥ 8 Tage) vorangehender Fondaparinuxgabe. Die Rate an Komplikationen war niedrig: es traten eine progrediente venöse Thrombose, jedoch keine „Major“-Blutungskomplikationen, HIT, allergische Hautreaktionen oder Todesfälle auf. Schlussfolgerung: Überraschenderweise wie-sen >75% der Patienten nach 24 Stunden Talspiegel auf, die noch im prophylaktischen Zielbereich lagen. Eine vermehrte Inzidenz von Blutungskomplikationen war nicht zu verzeichnen. Um eine Aussage treffen zu können, ob und ab welchen gemessenen Anti-Xa-Spiegeln mit einem gehäuften Auftreten von Blutungen zu rechnen ist, und wann eine prophylaktische Therapie mit Fondaparinux präoperativ/-interventionell abgesetzt warden sollte, sind größere Fallzahlen solcher Patienten notwendig, die sich einer Operation oder einer Intervention unterziehen. * equal contributors


  • Assays for Measuring Rivaroxaban: Their Suitability and Limitations

    by Edelgard Lindhoff-Last, Meyer Michel Samama, Thomas L Ortel, Jeffrey I Weitz, Theodore E Spiro

    Several new oral anticoagulants such as rivaroxaban (which targets Factor Xa) and dabigatran etexilate (which targets thrombin) are in advanced stages of clinical development and are already available for clinical use in some countries. Although these agents do not require routine coagulation monitoring, assays to assess the level of anticoagulation may be of assistance in certain circumstances such as in case of overdose, in patients with a hemorrhagic or thromboembolic event during treatment, or to assess compliance. Moreover, the influence of the new oral anticoagulants on routine coagulation tests must be recognized. The prothrombin time is not suitable for rivaroxaban measurement for several reasons, and the routinely used international normalized ratio for monitoring the vitamin K antagonists cannot be applied to rivaroxaban. Development of universal assays is challenging because the new oral anticoagulants have different targets, and even those with the same target have variable effects on routine coagulation assays. Focusing on rivaroxaban, there is emerging evidence that an anti-Factor Xa assay that uses rivaroxaban-containing plasma calibrators may provide the optimal method for determining plasma rivaroxaban concentrations.


    • 1 December 2008
      • Vol. 28  (5) , 365-75

    [Update thrombophilia].

    by E Lindhoff-Last, B Luxembourg, I Pabinger

    A survey on definitions, epidemiology, clinical manifestations of congenital and acquired thrombophilias is given with focus on evidence-based data. Diagnostic and therapeutical strategies are presented. Selective thrombophilia screening based on previous personal and/or family history of venous thromboembolism is more cost-effective than universal screening in all patient groups. In the majority of patients with venous thrombosis the results of thrombophilia screening do not influence the duration of oral anticoagulation. The only patient population who clearly profits from thrombophilia screening in this situation are patients with a newly diagnosed antiphospholipid syndrome, because prolonged anticoagulation can avoid the high incidence of recurrence in this patient population. Because of the increased risk of venous thrombosis during pregnancy and the puerperium, thrombophilia screening is indicated in selected patients with a previous history of venous thrombosis to be able to decide whether anticoagulation is necessary when these patients become pregnant. Significant associations with early and late pregnancy loss are observed for patients with thrombophilia while it remains unknown whether these patients profit from anticoagulation with heparin or low dose aspirin during their next pregnancy since placebo-controlled multicenter trials are not yet available.

  • Evidence-based indications for thrombophilia screening

    by Lindhoff- Last, B Luxembourg

    Thrombophilic defects have been shown to be associated with an increased risk of venous thrombosis, fetal loss, and gestational complications. The knowledge about the clinical relevance of thrombophilic defects is increasing, and evidence-based indications for thrombophilia screening are therefore discussed in this review. Selective thrombophilia screening based on previous personal and/or family history of venous thromboembolism is more cost-effective than universal screening in all patient groups evaluated. In the majority of patients with acute venous thrombosis, the results of thrombophilia screening do not influence the duration of oral anticoagulation. The only patient population who clearly profits from thrombophilia screening in this situation are patients with a newly diagnosed antiphospholipid syndrome, because prolonged anticoagulation can avoid the high incidence of recurrence in this patient population. Because of the increased risk of venous thrombosis during pregnancy and the puerperium, thrombophilia screening is indicated in selected patients with a previous history of venous thrombosis or a positive family history. Significant associations with early and late pregnancy loss are observed for carriers of the heterozygous factor V Leiden mutation, the heterozygous prothrombin-mutation G20210A and anticardiolipin antibodies, while protein S deficiency is significantly associated with late pregnancy loss. Antithrombotic drugs like UFH, LMWH or low-dose aspirin may have a potential therapeutic benefit in patients with recurrent pregnancy loss and thrombophilia, but placebo-controlled, multicenter trials are urgently needed to clarify this issue. Although a supra-additive effect for the risk of venous thrombosis is observed between oral contraceptives and some thrombophilias, the absolute incidence of venous thromboembolism is low in premenopausal women and mass screening strategies are therefore unlikely to be effective. While antiphospholipid antibodies are known to be associated with arterial thrombosis, screening for heritable thrombophilias is not useful in arterial thrombosis, although subgroup analysis indicates that they may play a role particularly in young patients and children.


  • Update Thrombophilie

    by B. Luxembourg, I. Pabinger, E. Lindhoff-Last

    Zusammenfassung: Es wird ein Überblick über Definitionen, Epidemiologie, Klinik der angeborenen und erworbenen Thrombophilien gegeben, wobei der Fokus auf evidenzbasierten Daten liegt. Selektives Thrombophilie-Screening, das auf einer positiven Eigen- und/oder Familienanamnese beruht, ist wesentlich kosteneffektiver als ein universelles Screening. Bei der Mehrzahl der Patienten mit venösen Thrombosen beeinflussen die Ergebnisse eines Thrombophilie-Screenings nicht die Therapiedauer mit oralen Antikoagulanzien. Die einzige Gruppe, die eindeutig von einem Screening in dieser Situation profitiert, sind Patienten mit einem Anti - phospholipidsyndrom, da bei ihnen durch eine prolongierte Antikoagulation das hohe Rezidivthromboserisiko minimiert werden kann. Da das Thromboserisiko während einer Schwangerschaft und im Wochenbett deutlich erhöht ist, kann ein Screening bei ausgewählten Patientinnen mit venösen Thrombosen in der Vorgeschichte indiziert sein, um daraus ggf. eine Indikation für eine Antikoagulation während der Schwangerschaft und im Wochenbett abzuleiten. Darüber hinaus lassen sich signifikante Assoziationen von thrombophilen Neigungen mit Früh- und Spätaborten nachweisen, wobei unklar bleibt, inwieweit Heparine oder Low-dose-Aspirin als Therapeutika bei betroffenen Frauen in einer nachfolgenden Schwangerschaft eingesetzt werden sollen, da multizentrische, placebokontrollierte Studien für diese Indikationen noch ausstehen.


  • ETIOLOGY, CLINICAL COURSE AND TREATMENT OUTCOME OF PATIENTS WITH INFERIOR VENA CAVA THROMBOSIS

    by B. Linnemann, H. Schmidt, M. Schindewolf, D. Zgouras, M. Erbe, R. Grossmann, E. Lindhoff-Last

  • ARE PATIENTS WITH THROMBOPHILIA AND A HISTORY OF VENOUS THROMBOEMBOLISM AT HIGHER RISK TO ARTERIAL THROMBOTIC EVENTS?

    by B. Linnemann, M. Schindewolf, D. Zgouras, M. Erbe, M. Jarosch-Preusche, B. Luxembourg, E. Lindhoff-Last

    • 1 May 2007
      • Vol. 27  (2) , 89-97

    [Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases].

    by M Schindewolf, H N Magnani, E Lindhoff-Last

    During the use of fractionated or unfractionated heparin adverse events frequently occur that can endanger the continuation of therapy. Especially in pregnant patients with thromboembolic complications it may be difficult to find a suitable alternative anticoagulant when heparin-induced thrombocytopenia type II (HIT II) or allergic skin reactions occur. There are still limited data on the use of danaparoid in pregnancy. The main reason for heparin intolerance in the 59 reviewed pregnancies were either HIT II, described in 37/59 (62.7%) pregnancies, or cutaneous adverse effects in 19/22 (86.4%) of non-HIT-associated pregnancies (22/59, 37.3%). 40/59 pregnancies were carried to term under use of danaparoid and resulted in the delivery of a healthy infant. In 16/19 pregnancies, danaparoid was stopped due to a major adverse event. Five patients showed bleeding complications, seven fetal losses were documented, but there was no association with the use of danaparoid. In 31/59 (52.5%) pregnancies adverse events were documented, 14/31 (45.2%) could be attributed to danaparoid. Anti-Xa-activity was not detected in five fetal cord blood samples and in four maternal breast-milk samples. Danaparoid can be used as an alternative anticoagulant in pregnant women with high risk for thrombosis and heparin intolerance.


    • 1 February 2007
      • Vol. 27  (1) , 22-31

    [Genomic diagnosis of thrombophilia in women: clinical relevance].

    by B Luxembourg, E Lindhoff-Last

    The detection of the DNA-sequence of human coagulation factors and inhibitors has introduced the possibility of differentiated mutation analysis in patients with venous thrombosis. Since venous thromboembolism is a multifactorial disease, women are at an increased risk to develop venous thrombosis due to hormonal contraception, during pregnancy and the puerperium. In addition, pregnancy complications like early or late fetal loss, pregnancy-induced hypertensive disorders and very recently recurrent embryo implantation failure have been suspected to be associated with thrombophilia. Therefore, it is of major importance to define inherited thrombophilic disorders, in which genetic diagnosis is of clinical relevance. While most of the genetic defects described so far represent a risk factor for venous thrombosis, only a minority of these defects actually needs DNA analysis to be detected: mutation analysis is clinically relevant, when factor V Leiden mutation is suspected, because relative risks concerning venous thrombosis as well as pregnancy complications clearly differ between homozygote and heterozygote forms of this frequently observed mutation. Similarly detection of the prothrombin mutation G20210A is of clinical relevance, although data for the very rarely observed homozygote variant are not sufficiently available. In contrast, detection of the homozygote variant of the MTHFR-mutation C677T is not useful, since clinical relevance could not be proven in a majority of studies concerning women specific risk situations. Inherited deficiencies of antithrombin, protein C and protein S are rare with high rates of different mutations. Genetic analysis seems only useful in patients with wide intraindividual variations of coagulation inhibitor activities. Genetic analysis concerning the PAI-1 4G/5G polymorphism or the factor XIII Val34Leu polymorphism can not be recommended in women specific risk situations because of insufficient data.


  • Danaparoid in der Schwangerschaft bei Heparinunverträglichkeit

    by H. N. Magnani, E. Lindhoff-Last, M. Schindewolf

    Zusammenfassung: Unter Therapie mit unfraktioniertem oder niedermolekularem Heparin treten häufig unerwünschte Arzneimittelwirkungen auf, die eine Fortsetzung der Therapie unmöglich machen. Insbesondere bei Schwangeren mit thromboembolischen Komplikationen kann es schwierig sein, ein geeignetes alternatives Antikoagulans zu finden, wenn zusätzlich eine Heparinunverträglichkeit vorliegt. Für den Einsatz von Danaparoid in der Schwangerschaft gibt es nur wenige Daten. Die Hauptgründe in den untersuchten 59 Schwangerschaften für eine Heparinunverträglichkeit waren entweder eine HIT II bei 37/59 (62,7%) Schwangeren, oder eine kutane Nebenwirkung in 19/22 (86,4%) der nicht HIT-assoziierten Schwangerschaften (22/59, 37,3%). Ergebnisse: 40/59 Schwangerschaften konnten unter Danaparoid erfolgreich ausgetragen werden, bei 16/19 wurde die Therapie aufgrund unerwünschter Arzneimittelwirkungen beendet. Fünf Patientinnen zeigten Blutungskomplikationen, die ebenso wenig Danaparoid-assoziiert waren wie die berichteten sechs Aborte und eine Abruptio. In 31/59 (52,5%) Schwangerschaften traten unerwünschte Arzneimittelwirkungen auf, 14/31 (45,2%) ließen sich auf Danaparoid zurückführen. In fünf Nabelschnurblut- und vier Brustmilchproben konnte keine Anti- Xa-Aktivität gemessen werden. Schlussfolgerung: Danaparoid kann zur alternativen Antikoagulation bei Schwangeren mit hohem Thromboserisiko und Heparinunverträglichkeit eingesetzt werden.